- Trial Name
- BIIB115
- Age:
- 6 months to 55 years old.
- Aim:
- To evaluate the safety and tolerability of BIIB115 (IT) bolus injection to healthy male participants (Part A) and to paediatric SMA participants previously treated with onasemnogene abeparvovec (Part B). The secondary objective is to evaluate the pharmacokinetics (PK) of BIIB115 (IT) bolus injection to healthy male participants (Part A) and to paediatric SMA participants who previously received onasemnogene abeparvovec (Part B).
- Status:
- Recruiting
- Locations:
- Netherlands, Beligum, Canada, France, Germany, Israel, Italy, Republic of Korea, Poland, UK
- Identifier:
- NCT05575011
Clinical Trials
Overview
BIIB115
BIIB115 is an investigational antisense oligonucleotide (ASO) developed by Biogen for the treatment of SMA, that may have the potential to help address additional unmet needs, as well as to be administered at extended dosing intervals.
Method of Action
Like nusinersen, BIIB115 will boost the production of full-length SMN protein.
Trial of BIIB115
Community updates & Press releases
- 4th January 2022: Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA - Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA | Biogen
- 8th March 2022: Biogen develops BIIB115, a potential new treatment for SMA - SMA Europe | News | Biogen develops BIIB115 (sma-europe.eu)